Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ChromaDex Corporation

< Previous 1 2 3 Next >
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Named Brianna Gerber Chief Financial Officer
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Present at the LD Micro Invitational
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Corporation Reports First Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio
From ChromaDex Corporation
Via Business Wire
Tickers CDXC
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.